It was indicated that PPARγ agonist TZDs, improve memory performances in patients suffering from AD and in transgenic animal models of AD by improving glucose hemostasis and suppression of pro-inflammatory signaling in the brain (Cheng et al., 2016 ▶; Masciopinto et al., 2012 ▶). The gene discussed is PPARG; the disease is Alzheimer disease.